Holen Sie sich die Stockscreener-App
4.14
1.19%
-0.05
Handel nachbörslich:
4.16
0.02
+0.48%
Schlusskurs vom Vortag:
$4.19
Offen:
$4.18
24-Stunden-Volumen:
204.89K
Relative Volume:
0.33
Marktkapitalisierung:
$91.40M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-94.11M
KGV:
-0.6889
EPS:
-6.01
Netto-Cashflow:
$-86.06M
1W Leistung:
-3.50%
1M Leistung:
-7.38%
6M Leistung:
+82.38%
1J Leistung:
-28.00%
1-Tages-Spanne:
$4.14
$4.19
1-Wochen-Bereich:
$4.14
$4.2848
52-Wochen-Spanne:
$1.78
$6.98
Adverum Biotechnologies Inc Stock (ADVM) Company Profile
Firmenname
Adverum Biotechnologies Inc
Sektor
Branche
Telefon
(650) 649-1004
Adresse
100 CARDINAL WAY, REDWOOD CITY, CA
Vergleichen Sie ADVM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADVM
Adverum Biotechnologies Inc
|
4.14 | 92.50M | 0 | -94.11M | -86.06M | -6.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-07 | Hochstufung | Truist | Hold → Buy |
| 2021-07-23 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-05-03 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-04-29 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-04-29 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-04-29 | Herabstufung | Truist | Buy → Hold |
| 2020-12-16 | Eingeleitet | UBS | Neutral |
| 2020-11-12 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2020-06-26 | Herabstufung | Raymond James | Mkt Perform → Underperform |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-05 | Hochstufung | SunTrust | Hold → Buy |
| 2020-04-28 | Eingeleitet | Goldman | Buy |
| 2020-03-16 | Eingeleitet | SVB Leerink | Outperform |
| 2020-02-10 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-02-10 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2019-10-15 | Bestätigt | Chardan Capital Markets | Neutral |
| 2019-09-13 | Bestätigt | Chardan Capital Markets | Neutral |
| 2019-06-14 | Fortgesetzt | Raymond James | Mkt Perform |
| 2018-11-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-02 | Herabstufung | SunTrust | Buy → Hold |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-08-30 | Eingeleitet | SunTrust | Buy |
| 2018-02-15 | Fortgesetzt | Piper Jaffray | Overweight |
| 2017-10-12 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Adverum Biotechnologies Inc Aktie (ADVM) Neueste Nachrichten
Adverum Biotechnologies Faces Lease Termination Notice - TipRanks
Adverum Biotechnologies IncARE-NC Region No. 21 LLC terminates certain lease agreement with Adverum BiotechnologiesSEC filing - MarketScreener
Chart overlay techniques for tracking Adverum Biotechnologies Inc.2025 Price Targets & Low Risk Growth Stock Ideas - newser.com
Is Adverum Biotechnologies Inc. stock cheap compared to fundamentals2025 Retail Activity & Weekly High Momentum Picks - newser.com
Lilly strengthens gene therapy portfolio with MeiraGTx and Adverum deals - Drug Discovery News
Why Adverum Biotechnologies Inc. stock remains on watchlistsJuly 2025 Levels & Weekly High Conviction Ideas - newser.com
Why Adverum Biotechnologies Inc. (AVU0) stock trades below fair valueJuly 2025 Action & Risk Managed Trade Strategies - newser.com
Will Adverum Biotechnologies Inc. stock maintain growth storyMarket Growth Report & Safe Swing Trade Setups - newser.com
Why retail traders accumulate Adverum Biotechnologies Inc. (AVU0) stockQuarterly Risk Review & Low Drawdown Trading Strategies - newser.com
Has Adverum Biotechnologies Inc. found a price floor2025 Risk Factors & Low Risk High Reward Ideas - newser.com
Volume spikes in Adverum Biotechnologies Inc. stock – what they mean2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
Will Adverum Biotechnologies Inc. (AVU0) stock benefit from mergersJuly 2025 Summary & Scalable Portfolio Growth Methods - newser.com
The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum - sharewise.com
Published on: 2025-11-19 05:22:39 - newser.com
Will Adverum Biotechnologies Inc. stock deliver consistent dividends2025 Support & Resistance & Long-Term Growth Stock Strategies - newser.com
Published on: 2025-11-18 23:52:15 - newser.com
Why analysts maintain buy rating on Adverum Biotechnologies Inc. (AVU0) stockWatch List & Target Return Focused Picks - newser.com
Halper Sadeh LLC Encourages CMA, ADVM, HOUS Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
This Yum! Brands Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Benzinga
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
HC Wainwright Downgrades Adverum Biotechnologies to Neutral From Buy, Adjusts PT to $5 From $30 - MarketScreener
H.C. Wainwright downgrades Adverum stock to Neutral following Eli Lilly acquisition - Investing.com Canada
This Dell Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday - Benzinga
HC Wainwright Downgrades Adverum Biotechnologies to Neutral From Buy, Price Target is $5 - MarketScreener
Detecting price anomalies in Adverum Biotechnologies Inc. with AIWeekly Stock Analysis & AI Enhanced Market Trend Forecasts - newser.com
Finanzdaten der Adverum Biotechnologies Inc-Aktie (ADVM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
1.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):